+

WO2003048359A1 - Markers for sugar/lipid metabolic disorders and utilization thereof - Google Patents

Markers for sugar/lipid metabolic disorders and utilization thereof Download PDF

Info

Publication number
WO2003048359A1
WO2003048359A1 PCT/JP2002/012793 JP0212793W WO03048359A1 WO 2003048359 A1 WO2003048359 A1 WO 2003048359A1 JP 0212793 W JP0212793 W JP 0212793W WO 03048359 A1 WO03048359 A1 WO 03048359A1
Authority
WO
WIPO (PCT)
Prior art keywords
sugar
metabolic disorders
lipid metabolic
markers
utilization
Prior art date
Application number
PCT/JP2002/012793
Other languages
French (fr)
Japanese (ja)
Inventor
Junji Ichihara
Eiji Sugaru
Mutsuo Taiji
Original Assignee
Sumitomo Pharmaceuticals Company, Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Pharmaceuticals Company, Limited filed Critical Sumitomo Pharmaceuticals Company, Limited
Priority to AU2002361078A priority Critical patent/AU2002361078A1/en
Publication of WO2003048359A1 publication Critical patent/WO2003048359A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11025—Mitogen-activated protein kinase kinase kinase (2.7.11.25), i.e. MAPKKK or MAP3K
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Emergency Medicine (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Endocrinology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

It is intended to provide polynucleotides having at least 15 consecutive bases in the base sequence of MLTK gene and/or polynucleotides complementary to these polynucleotides, as disease markers for sugar/lipid metabolic disorders; a method of detecting sugar/lipid metabolic disorders with the use of these disease markers; and a method of screening a drug useful in ameliorating these diseases.
PCT/JP2002/012793 2001-12-05 2002-12-05 Markers for sugar/lipid metabolic disorders and utilization thereof WO2003048359A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002361078A AU2002361078A1 (en) 2001-12-05 2002-12-05 Markers for sugar/lipid metabolic disorders and utilization thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2001371420 2001-12-05
JP2001-371420 2001-12-05
JP2002-41542 2002-02-19
JP2002041542A JP2003230388A (en) 2001-12-05 2002-02-19 Disorders of glucose and lipid metabolism disorders and their use

Publications (1)

Publication Number Publication Date
WO2003048359A1 true WO2003048359A1 (en) 2003-06-12

Family

ID=26624888

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/012793 WO2003048359A1 (en) 2001-12-05 2002-12-05 Markers for sugar/lipid metabolic disorders and utilization thereof

Country Status (3)

Country Link
JP (1) JP2003230388A (en)
AU (1) AU2002361078A1 (en)
WO (1) WO2003048359A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005118833A3 (en) * 2004-06-01 2006-05-11 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with sterile-alpha motif and leucine zipper containing kinase (zak)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005021792A1 (en) * 2003-08-28 2005-03-10 Dainippon Sumitomo Pharma Co., Ltd. Preventive or remedy for inflammatory bowel diseases containing anti-cd81 antibody as the active ingredient

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0735370A1 (en) * 1995-03-28 1996-10-02 Takeda Chemical Industries, Ltd. Method for assaying map kinase
WO1998053050A2 (en) * 1997-05-21 1998-11-26 The Children's Medical Center Corporation Short peptides which selectively modulate the activity of serine/threonine kinases
WO2000014212A1 (en) * 1998-09-09 2000-03-16 Millennium Pharmaceuticals, Inc. Novel protein kinase molecules and uses therefor
WO2001012670A1 (en) * 1999-08-13 2001-02-22 Human Genome Sciences, Inc. Tgf-beta receptor polynucleotides, polypeptides, and antibodies

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0735370A1 (en) * 1995-03-28 1996-10-02 Takeda Chemical Industries, Ltd. Method for assaying map kinase
WO1998053050A2 (en) * 1997-05-21 1998-11-26 The Children's Medical Center Corporation Short peptides which selectively modulate the activity of serine/threonine kinases
WO2000014212A1 (en) * 1998-09-09 2000-03-16 Millennium Pharmaceuticals, Inc. Novel protein kinase molecules and uses therefor
WO2001012670A1 (en) * 1999-08-13 2001-02-22 Human Genome Sciences, Inc. Tgf-beta receptor polynucleotides, polypeptides, and antibodies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ISAMU GOTOH ET AL.: "Identification and characterization of a novel MAP kinase kinase kinase, MLTK", THE JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, pages 4276 - 4286, XP002965828 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005118833A3 (en) * 2004-06-01 2006-05-11 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with sterile-alpha motif and leucine zipper containing kinase (zak)

Also Published As

Publication number Publication date
JP2003230388A (en) 2003-08-19
AU2002361078A1 (en) 2003-06-17

Similar Documents

Publication Publication Date Title
USD482368S1 (en) Display for touchscreen of a computer monitor
USD504923S1 (en) Dumbbell
EP3760234A3 (en) Rna interference for the treatment of gain-of-function disorders
AU2003301957A1 (en) Administration of anti-inflammatory drugs into the central nervous system
USRE40391E1 (en) Computer
USD491075S1 (en) Clock
USD499812S1 (en) Pregnancy testing stick
USD497393S1 (en) Combined sign and parking meter
USD471558S1 (en) Connector for computer
WO2002072604A3 (en) Genes and polymorphisms associated with cardiovascular disease and their use
AU2002336759A1 (en) Drug targets for alzheimer's disease and other diseases associated with decreased neuronal metabolism
USD495709S1 (en) Display monitor
USD517613S1 (en) Playing card
WO2003057874A1 (en) Disease markers for renal diseaes and utilization thereof
USD454931S1 (en) Computer for an exercise device
USD466416S1 (en) Clock
WO2003048359A1 (en) Markers for sugar/lipid metabolic disorders and utilization thereof
USD473868S1 (en) LCD monitor
USD479334S1 (en) Massager
USD482034S1 (en) LCD multimedia monitor
USD460612S1 (en) Shoe anklet
USD479485S1 (en) Christ banner
USD491935S1 (en) Multimedia computer
USD477317S1 (en) Computer
USD476904S1 (en) Clock

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载